Clinical Trials on GIST in Finland

Total 4 results

Novartis Pharmaceuticals

Active, not recruiting

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

GIST and CML

China, Turkey, Singapore, France, Switzerland, Thailand, United States, Romania, Hong Kong, Finland, United Kingdom
Pfizer

Completed

Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib

GIST

United States, Switzerland, Belgium, Denmark, Spain, United Kingdom, Australia, India, France, Slovakia, Canada, Finland, Germany, Korea, Republic of, Netherlands, Poland
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)

United States, Finland, Australia
Novartis Pharmaceuticals

Completed

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor (GIST)

United States

3

Subscribe